ECO Animal Health Group plc (id:3947 EAH)
66.00 GBP
Opening hours: 08:00 - 16:30 (GMT Standard Time: 11/22/2024 5:50:11 PM)
Exchange closed, opens in 2 days 14 hours
About ECO Animal Health Group plc
Market Capitalization 47.77M
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.
| Headquarters (address) |
The Grange London N14 6BN United Kingdom |
| Phone | 44 208 447 8899 |
| Website | https://www.ecoanimalhealthgroupplc.com |
| Employees | 227 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | EAH |
| Exchange | London Stock Exchange |
| Currency | GBP |
| 52 week range | 60.00 - 135.00 |
| Market Capitalization | 47.77M |
| Dividend yield forward | 6.06 % |
| Dividend yield forward United Kingdom (ID:3, base:499) | 7.27 % |
| P/E trailing | 35.25 |
| P/E forward | 0.334 |
| Price/Sale | 0.534 |
| Price/Book | 57.09 |
| Beta | 0.030 |
| EPS | 0.020 |
| EPS United Kingdom (ID:3, base:637) | 0.429 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ECO Animal Health Group plc has raised their dividend 6.06 years in a row. This is below the 41168.083800 year average in the 'Drug Manufacturers Specialty & Generic' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ECO Animal Health Group plc has raised their dividend 6.06 years in a row. This is below the 41168.083800 year average in the 'Drug Manufacturers Specialty & Generic' industry